MX9304627A - Composiciones de amifostina cristalina y metodos para la preparacion y el uso de las mismas. - Google Patents

Composiciones de amifostina cristalina y metodos para la preparacion y el uso de las mismas.

Info

Publication number
MX9304627A
MX9304627A MX9304627A MX9304627A MX9304627A MX 9304627 A MX9304627 A MX 9304627A MX 9304627 A MX9304627 A MX 9304627A MX 9304627 A MX9304627 A MX 9304627A MX 9304627 A MX9304627 A MX 9304627A
Authority
MX
Mexico
Prior art keywords
compositions
present
crystalline
preparation
methods
Prior art date
Application number
MX9304627A
Other languages
English (en)
Inventor
Paul E Kennedy
Roger A Rajewski
John M Baldoni
Original Assignee
Us Bioscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26795942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9304627(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/099,298 external-priority patent/US5424471A/en
Application filed by Us Bioscience filed Critical Us Bioscience
Publication of MX9304627A publication Critical patent/MX9304627A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Insulating Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Sub-Exchange Stations And Push- Button Telephones (AREA)

Abstract

La presente invención se refiere a una composición de amisfostina cristalina secada en vació térmicamente estable, estéril, y, opcionalmente, el (los) excipiente (s) farmacéuticamente aceptable (s). En forma típica, las composiciones cristalinas de la presente invención presentan una estabilidad mejorada en niveles de temperatura ubicados desde aproximadamente 4 grados centígrados hasta la temperatura ambiente durante un período de cuando menos 2 años de relación con las preparaciones de amifostina amorías sólidas existentes. Las composiciones reconstituidas de la presente invención son adecuadas para su administración a seres humanos como agente protector contra efectos radiológicos o químicos.
MX9304627A 1992-07-31 1993-07-30 Composiciones de amifostina cristalina y metodos para la preparacion y el uso de las mismas. MX9304627A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92292992A 1992-07-31 1992-07-31
US08/099,298 US5424471A (en) 1992-07-31 1993-07-29 Crystalline amifostine compositions and methods of the preparation and use of same

Publications (1)

Publication Number Publication Date
MX9304627A true MX9304627A (es) 1994-04-29

Family

ID=26795942

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304627A MX9304627A (es) 1992-07-31 1993-07-30 Composiciones de amifostina cristalina y metodos para la preparacion y el uso de las mismas.

Country Status (23)

Country Link
US (1) US5591731A (es)
EP (1) EP0655917B1 (es)
JP (1) JP3503943B2 (es)
CN (2) CN1070370C (es)
AT (1) ATE261729T1 (es)
AU (1) AU681858B2 (es)
CA (1) CA2120133C (es)
CZ (1) CZ284417B6 (es)
DE (1) DE69333453T2 (es)
DK (1) DK0655917T3 (es)
ES (1) ES2215992T3 (es)
HK (1) HK1010692A1 (es)
HU (1) HU227122B1 (es)
IL (1) IL106540A (es)
IS (1) IS1843B (es)
MX (1) MX9304627A (es)
NO (2) NO309636B1 (es)
NZ (1) NZ255182A (es)
PL (1) PL178463B1 (es)
PT (1) PT655917E (es)
RU (1) RU2125880C1 (es)
SG (1) SG47101A1 (es)
SK (1) SK283318B6 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573253B2 (en) 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
US6051563A (en) 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6239119B1 (en) 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
US6017922A (en) * 1998-05-18 2000-01-25 U.S. Bioscience, Inc. Thermally stable trimetrexates and processes for producing the same
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6384259B1 (en) * 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
DE10043170C2 (de) * 2000-09-01 2002-10-24 Klinge Co Chem Pharm Fab Amifostin-Monohydrat und Verfahren zu seiner Herstellung
CN1148192C (zh) * 2000-10-19 2004-05-05 南京振中生物工程有限公司 细胞保护剂氨磷汀制剂及其制备方法
US7053072B2 (en) * 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
CN1649614A (zh) 2002-02-22 2005-08-03 新河药品股份有限公司 活性剂传递系统和保护及施用活性剂的方法
US7629333B2 (en) * 2002-03-29 2009-12-08 Medimmune, Llc Stable amorphous amifostine compositions and methods for the preparation and use of same
CN1305478C (zh) * 2004-05-12 2007-03-21 天津市资福医药科技开发有限公司 氨磷汀冻干制剂及其制备方法
DK2343304T3 (en) 2005-02-16 2015-06-29 Anacor Pharmaceuticals Inc BIOCIDE BORONOPHTHALIDE COMPOUNDS
WO2007047315A1 (en) * 2005-10-20 2007-04-26 Albemarle Corporation Amifostine dihydrate crystalline composition
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
RU2008131324A (ru) 2005-12-30 2010-02-10 Анакор Фармасьютикалз, Инк. (Us) Борсодержащие малые молекулы
CA2933994A1 (en) 2006-02-16 2007-08-23 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
US20090239817A1 (en) * 2006-04-17 2009-09-24 Goverment Of The United States Of America, As Represented By The Secretary, Dept Of Health Organic thiophosphate antiretroviral agents
US9585849B2 (en) 2006-04-17 2017-03-07 The Burlington Hc Research Group, Inc. Broad spectrum antiviral and methods of use
WO2008060441A2 (en) * 2006-11-09 2008-05-22 Scidose Llc Stable amifostine liquid concentrate
RU2547441C2 (ru) 2008-03-06 2015-04-10 Анакор Фармасьютикалз, Инк. Борсодержащие малые молекулы в качестве противовоспалительных агентов
WO2009140309A2 (en) * 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
CN101412732B (zh) * 2008-09-02 2011-09-07 大连美罗药业股份有限公司 三水合3-氨基丙基胺乙基硫代磷酸高纯稳定晶体及其制备方法
CN101347412B (zh) * 2008-09-02 2011-07-27 大连美罗药业股份有限公司 三水合氨磷汀结晶冻干制剂及其制备方法
WO2010028005A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
EP2348863A4 (en) * 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
US9493489B2 (en) * 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
BRPI0922566A2 (pt) * 2008-12-17 2017-03-28 Anacor Pharmaceuticals Inc polimorfo cristalino, composição farmacêutica, composto, e, métodos para preparar um composto, e para tratar uma doença.
WO2011017125A1 (en) * 2009-07-28 2011-02-10 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
US9440994B2 (en) * 2009-08-14 2016-09-13 Anacor Pharmaceuticals, Inc. Boron containing small molecules as antiprotozoal agents
WO2011022337A1 (en) * 2009-08-19 2011-02-24 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011037731A1 (en) * 2009-09-25 2011-03-31 Anacor Pharmaceuticals, Inc. Boron containing small molecules
US9346834B2 (en) 2009-10-20 2016-05-24 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
US8461134B2 (en) * 2009-11-11 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
LT2501234T (lt) * 2009-11-20 2017-12-11 Tonix Pharma Holdings Limited Būdai ir kompozicijos, skirti simptomų, susijusių su potrauminiu streso sutrikimu, gydymui naudojant ciklobenzapriną
WO2011094450A1 (en) 2010-01-27 2011-08-04 Anacor Pharmaceuticals, Inc Boron-containing small molecules
AP2012006482A0 (en) 2010-03-19 2012-10-31 Anacor Pharmacueticals Inc Boron-containing small molecules as anti-protozoalagent
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
EA033311B1 (ru) 2010-09-07 2019-09-30 Анакор Фармасьютикалс, Инк. Производные бензоксаборола в качестве антибактериальных средств
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
TWI432204B (zh) * 2011-06-03 2014-04-01 Taiwan Hopax Chems Mfg Co Ltd 對抗自由基的醫藥組合物
CN102286020A (zh) * 2011-07-11 2011-12-21 大连美罗大药厂 一水合3-氨基丙基胺乙基硫代磷酸的制备方法
HRP20240648T1 (hr) 2013-03-15 2024-08-02 Tonix Pharma Holdings Limited Eutektičke formulacije ciklobenzaprin hidroklorida i manitola
CA2915708C (en) * 2013-06-18 2018-02-06 Aminomedix Inc. Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids
CA2961822A1 (en) 2014-09-18 2016-03-24 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride
US9931357B2 (en) * 2014-10-02 2018-04-03 Cytosorbents Corporation Use of gastrointestinally administered porous enteron sorbent polymers to prevent or treat radiation induced mucositis, esophagitis, enteritis, colitis, and gastrointestinal acute radiation syndrome
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
CN118267382A (zh) 2017-12-11 2024-07-02 通尼克斯制药控股有限公司 用于痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗
CN110616463B (zh) * 2018-10-30 2024-03-22 中国科学院化学研究所 一种制备有机半导体分子单晶或无定型物的方法
CN110607552B (zh) * 2018-10-30 2024-02-20 中国科学院化学研究所 一种利用水溶液制备单晶或无定型物的方法
CN110735177B (zh) * 2018-10-30 2024-03-22 中国科学院化学研究所 一种利用溶液冻结制备单晶或无定型物的方法
CN110735176B (zh) * 2018-10-30 2024-03-22 中国科学院化学研究所 一种制备配位化合物单晶或无定型物的方法
CN110606868A (zh) * 2018-10-30 2019-12-24 中国科学院化学研究所 一种制备多肽或蛋白质单晶或无定型物的方法
CN110607551B (zh) * 2018-10-30 2024-02-20 中国科学院化学研究所 一种制备食品添加剂单晶或无定型物的方法
CN110607553B (zh) * 2018-10-30 2024-03-22 中国科学院化学研究所 一种制备粒径可调的药物或药物中间体单晶或无定型物的方法
EP3824880A1 (en) * 2019-11-25 2021-05-26 Clevexel Pharma Freeze-dried powder containing 2-[(3-aminopropyl)amino]ethanethiol and its use for preparing a thermogel
KR20240041506A (ko) * 2022-09-23 2024-04-01 주식회사 경보제약 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892824A (en) * 1968-12-16 1975-07-01 Southern Res Inst S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates
JPS6041676B2 (ja) * 1977-09-21 1985-09-18 山之内製薬株式会社 Ｓ−２−（３−アミノプロピルアミノ）エチルジハイドロジエンホスホロチオエ−ト１水和結晶の新規製法
US4424216A (en) * 1979-07-31 1984-01-03 The Rockefeller University Method for the reduction of mucin viscosity
ATE82505T1 (de) * 1984-08-08 1992-12-15 Survival Technology Absorptionsverbesserer.
CA2057900A1 (en) * 1989-05-24 1990-11-25 Philip S. Schein Method for protection from azt side effects and toxicity

Also Published As

Publication number Publication date
CA2120133A1 (en) 1994-02-17
PL178463B1 (pl) 2000-05-31
SG47101A1 (en) 1998-03-20
NO309636B1 (no) 2001-03-05
CN1146428C (zh) 2004-04-21
NO20005775D0 (no) 2000-11-15
PL307298A1 (en) 1995-05-15
HK1010692A1 (en) 1999-06-25
EP0655917A4 (en) 1995-08-02
CN1307870A (zh) 2001-08-15
HU9500277D0 (en) 1995-03-28
AU681858B2 (en) 1997-09-11
PT655917E (pt) 2004-08-31
EP0655917A1 (en) 1995-06-07
US5591731A (en) 1997-01-07
AU4796693A (en) 1994-03-03
NO950343D0 (no) 1995-01-30
SK11395A3 (en) 1995-07-11
CZ284417B6 (cs) 1998-11-11
NZ255182A (en) 1996-12-20
ATE261729T1 (de) 2004-04-15
DK0655917T3 (da) 2004-07-26
HUT70191A (en) 1995-09-28
CA2120133C (en) 1998-06-09
SK283318B6 (sk) 2003-05-02
IS1843B (is) 2003-01-30
JPH08500104A (ja) 1996-01-09
CN1070370C (zh) 2001-09-05
IS4060A (is) 1994-02-01
NO315691B1 (no) 2003-10-13
RU2125880C1 (ru) 1999-02-10
NO950343L (no) 1995-03-22
CZ23095A3 (en) 1995-10-18
DE69333453D1 (de) 2004-04-22
IL106540A (en) 2000-02-17
IL106540A0 (en) 1994-08-26
EP0655917B1 (en) 2004-03-17
DE69333453T2 (de) 2005-01-27
HU227122B1 (en) 2010-07-28
CN1092980A (zh) 1994-10-05
NO5775A (no) 1995-03-22
JP3503943B2 (ja) 2004-03-08
ES2215992T3 (es) 2004-10-16

Similar Documents

Publication Publication Date Title
MX9304627A (es) Composiciones de amifostina cristalina y metodos para la preparacion y el uso de las mismas.
MY110631A (en) Crystalline amifostine compositions and methods for the preparation and use of same.
ATE218580T1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
ATE218582T1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
DE69635996D1 (de) Pharmazeutische zusammensetzungen mit hydroximsäurederivaten
IL97892A0 (en) 2,9-disubstituted-4h-pyrido(1,2-a)pyrimidin-4-ones,their preparation and pharmaceutical compositions containing them
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
KR910002437A (ko) 항염증성 조성물, 항알레르기성 조성물 또는 이들 혼합성질의 조성물
BR9807406A (pt) Formulação farmacêutica, e, processo para a preparação das mesmas
IT1234218B (it) Derivati terziobutilati di benzilidene canfora, procedimento per la loro preparazione,loro impiego come agenti anti ossidanti e composizioni cosmetiche e farmaceutiche che li contengono
IT1197516B (it) Derivati teofillinmetilanici e teofillinmetilditianici procedimento per la loro preparazione e composizioni farmaceutiche che li comprendono
DK527186A (da) Bronchodilaterende farmaceutisk praeparat
TR199900013T2 (xx) Yeni bile�ikler.
FR2642648B1 (fr) Utilisation de derives d'alkyl-5 pyridazine comme medicaments actifs sur le systeme cholinergique
MY101266A (en) Pharmaceutical formulations
NO974651L (no) Biologisk aktive ureidoderivater som er nyttige i behandlingen av multippel sklerose
IT1272762B (it) Derivati benz/e/indenici farmaceuticamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
DK0490311T3 (da) Derivater af 10,11,12,13-tetrahydro-desmycosin, fremgangsmåder til fremstilling deraf og anvendelse deraf til opnåelse af farmaceutiske præparater
SE8700829L (sv) Farmaceutisk komposition
ITMI912324A0 (it) Derivati dall'acido beta-idrossibutirrico, procedimento per la loro preparazione e relative composizioni farmaceutiche
SE8504708L (sv) Nya nukleosidderivat med antiherpesegenskaper, farmaceutiska kompositioner innehallande desamma och forfarande for framstellning av de aktiva bestandsdelarna